Pathway Financial Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-2,137
Closed -$258K 136
2026
Q1
$258K Sell
2,137
-1,150
-35% -$133K 0.03% 122
2025
Q4
$358K Hold
3,287
0.05% 109
2025
Q3
$276K Buy
3,287
+691
+27% +$56.9K 0.04% 120
2025
Q2
$205K Sell
2,596
-203
-7% -$16.1K 0.03% 127
2025
Q1
$251K Buy
2,799
+95
+4% +$8.87K 0.05% 144
2024
Q4
$269K Buy
+2,704
New +$279K 0.06% 134
2024
Q3
Sell
-2,270
Closed -$281K 172
2024
Q2
$281K Sell
2,270
-38
-2% -$4.89K 0.08% 123
2024
Q1
$305K Buy
2,308
+343
+17% +$42.3K 0.08% 123
2023
Q4
$214K Buy
+1,965
New +$204K 0.06% 150
2020
Q2
Sell
-3,563
Closed -$259K 105
2020
Q1
$259K Hold
3,563
0.09% 71
2019
Q4
$306K Buy
+3,563
New +$293K 0.09% 83
2018
Q3
Sell
-1,316
Closed -$76K 264
2018
Q2
$76K Sell
1,316
-262
-17% -$14.8K 0.04% 186
2018
Q1
$82K Hold
1,578
0.05% 182
2017
Q4
$85K Buy
+1,578
New +$87.5K 0.05% 179

Other funds holding MRK

Pathway Financial Advisors's MRK Position: Q2 2026 in Review

Pathway Financial Advisors sold out of Merck (MRK) in Q2 2026, closing a stake of 2,137 shares — an estimated $258K sold.

Pathway Financial Advisors first reported a position in MRK in Q4 2017 and held it in 14 quarters. The position peaked at $358K in Q4 2025. 711 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Pathway Financial Advisors reported no remaining Merck position as of Q2 2026 after selling out during the quarter.
  • Pathway Financial Advisors sold 2,137 Merck shares in Q2 2026, an estimated $258K.
  • Pathway Financial Advisors first reported a position in Merck in Q4 2017 and held it in 14 quarters.
  • Pathway Financial Advisors's Merck position peaked at $358K in Q4 2025.
  • 711 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Pathway Financial Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.